Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

N4 Pharma PLC

Healthcare GB N4P

NoneGBX
0.00(0%)

Last update at 2026-06-05T16:00:47.008413Z

Day Range

--
LowHigh

52 Week Range

0.351.00
LowHigh

Fundamentals

  • Previous Close 0.68
  • Market Cap3.95M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00707M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00707M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -1.22100M -1.42500M -1.19326M -1.84261M -1.56638M
Minority interest 0.06M 0.00745M - - -
Net income -1.05900M -1.26900M -1.02926M -1.54435M -1.30484M
Selling general administrative 0.55M 0.72M 0.62M 0.66M 0.66M
Selling and marketing expenses - 0.09M - - -
Gross profit 0.00728M 0.00195M - - -
Reconciled depreciation - - - - -
Ebit - -1.42417M -1.19326M -1.84329M -1.56442M
Ebitda -1.22100M -1.33500M -1.19326M -1.84329M -1.56442M
Depreciation and amortization - 0.09M - - -
Non operating income net other - - - - -
Operating income -1.22100M -1.42500M -1.19326M -1.84329M -1.56442M
Other operating expenses 1.23M 1.43M 1.19M 1.84M 1.56M
Interest expense - - 0.00000M 0.00068M 0.00196M
Tax provision -0.10111M -0.14782M -0.16400M -0.29827M -0.26154M
Interest income - 0.00000M 0.00000M 0.00068M 0.00196M
Net interest income - 0.00000M 0.00000M 0.00068M -0.00196M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.10100M -0.14800M -0.16400M -0.29827M -0.26154M
Total revenue 0.00728M 0.00195M 0.00000M 0.00000M 0.00000M
Total operating expenses 1.17M 1.43M 1.19M 1.84M 1.56M
Cost of revenue - - - - -
Total other income expense net - -0.00000M 0.00000M 0.00068M -0.00196M
Discontinued operations - - - - -
Net income from continuing ops -1.11999M -1.27678M -1.02926M -1.54435M -1.30484M
Net income applicable to common shares - - -1.02926M -1.54435M -1.30484M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 0.78M 1.28M 2.17M 2.34M 3.83M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.02M 0.01M 0.25M 0.56M 0.27M
Total liab 0.12M 0.08M 0.08M 0.21M 0.17M
Total stockholder equity 0.65M 1.13M 2.09M 2.13M 3.66M
Deferred long term liab - - - - -
Other current liab 0.10M 0.07M 0.04M 0.03M 0.05M
Common stock 1.58M 9.35M 0.94M 0.72M 0.72M
Capital stock 1.58M 1.08M 0.94M 0.72M 0.72M
Retained earnings -10.39901M -9.34127M -8.06141M -7.03215M -5.48781M
Other liab - - - - -
Good will 0.00000M 0.06M - - -
Other assets - 0.00000M - - -
Cash 0.63M 1.03M 1.92M 1.78M 3.56M
Cash and equivalents - - - - -
Total current liabilities 0.12M 0.08M 0.08M 0.21M 0.17M
Current deferred revenue - - - - -
Net debt -0.62597M -1.02711M -1.91953M -1.78402M -3.55558M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 9.47M 1.02M 9.21M 8.44M 8.42M
Property plant equipment - - - - -
Total current assets 0.78M 1.21M 2.17M 2.34M 3.83M
Long term investments - - - - -
Net tangible assets - - 2.09M 2.13M 3.66M
Short term investments - - - - -
Net receivables 0.13M 0.18M 0.21M 0.56M 0.25M
Long term debt - - - - -
Inventory - -0.17643M - - -
Accounts payable 0.02M 0.02M 0.04M 0.18M 0.12M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.11M 0.11M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 0.72M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -0.00000M - - -
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.06M 0.00000M 0.00000M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 0.00000M 0.00078M - - 0.00000M
Change to liabilities - - -0.13484M 0.04M 0.09M
Total cashflows from investing activities - 0.00078M - - -
Net borrowings - - - - -
Total cash from financing activities 0.57M 0.32M 0.96M 0.00068M 3.97M
Change to operating activities - - - - -
Net income -1.11999M -1.26933M -1.02926M -1.54435M -1.56638M
Change in cash -0.40114M -0.89242M 0.14M -1.77155M 2.59M
Begin period cash flow 1.03M 1.92M 1.78M 3.56M 0.97M
End period cash flow 0.63M 1.03M 1.92M 1.78M 3.56M
Total cash from operating activities -0.97150M -1.20910M -0.82826M -1.77223M -1.37907M
Issuance of capital stock 0.63M 0.35M 1.05M 0.00000M 3.97M
Depreciation - - - - -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.00946M 0.04M -0.03731M 0.01M -0.03053M
Sale purchase of stock - - - - 3.97M
Other cashflows from financing activities -0.05964M -0.03410M -0.09023M 0.00068M -0.00196M
Change to netincome - - 0.37M -0.28228M -0.25560M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.03M 0.05M -0.17215M 0.05M 0.06M
Stock based compensation 0.00739M 0.00343M 0.02M 0.02M 0.00398M
Other non cash items 0.11M 0.00873M 0.35M -0.29894M 0.12M
Free cash flow -0.97150M -1.20910M -0.82826M -1.77223M -1.37907M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
N4P
N4 Pharma PLC		 - -% - - - 559.49 2.12 285.55 -1.8199
GNS
Genus PLC		 - -% 2274.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 -9.7 6.93% 130.30 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 30.00 5.00% 630.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 1.50 2.14% 71.50 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.

N4 Pharma PLC

8 Bishopsgate, London, United Kingdom, EC2N 4BQ

Key Executives

Name Title Year Born
Mr. Nigel James Theobald Founder, CEO & Exec. Director 1964
Dr. David Templeton Exec. Director & Technical Director NA
Mr. Luke Sebastian Cairns Exec. Director 1978
Rob Harris Head of CMC Devel. NA
Dr. Andrew Leishman Consultant NA
Mr. Luke Sebastian Cairns Executive Director 1978
Dr. David Horn Solomon M.D. CEO & Director 1960
Rob Harris Head of CMC Development NA
Dr. Fiona McLaughlin FSB, Ph.D. Head of Research & Development 1970
Mr. Mark Edbrooke Ph.D. Head of Strategy NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.